gdc
FDA Approvals, News & UpdatesFollicular LymphomaNewsworthy

Aliqopa the Newest Treatment Approved for Relapsed Follicular Lymphoma

December 2017 Vol 3 No 6

On September 14, 2017, the FDA approved Aliqopa (copanlisib; from Bayer HealthCare) for the treatment of adults with relapsed follicular lymphoma who have received ≥2 previous systemic therapies.

“For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments. Options are limited for these patients and today’s approval provides an additional choice for treatment, filling an unmet need for them,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Aliqopa was based on a clinical trial showing improved response to therapy with this drug. Serious side effects with Aliqopa include infections, high blood sugar and blood pressure, inflammation of lung tissue, neutropenia, and severe skin reactions. Women who are breastfeeding should avoid this drug.

Recommended For You
FDA Approvals, News & Updates
FDA NEWs
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
FDA Approvals, News & Updates
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
In June, the FDA approved Zepzelca as the newest treatment for patients with metastatic small-cell lung cancer, an uncommon type of lung cancer with few treatment options.
Follicular LymphomaPatient Stories
Enduring Spirit
By Pam Neff
With a demanding career and 3 small children, Pam Neff had to make some difficult decisions during her treatment for an aggressive blood cancer.
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country